MDGL Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of -172.04% compared to Madrigal Pharmaceuticals's net margin of 25.86%. Madrigal Pharmaceuticals's return on equity of -89.04% beat Corcept Therapeutics's return on equity of 25.77%.

Madrigal Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 19.99%. On the other hand Corcept Therapeutics has an analysts' consensus of -- which suggests that it could grow by 47.15%. Given that Corcept Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Corcept Therapeutics is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.418, which suggesting that the stock is 141.819% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.513, suggesting its less volatile than the S&P 500 by 48.73%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $62.2M, which are smaller than Corcept Therapeutics quarterly revenues of $182.5M. Madrigal Pharmaceuticals's net income of -$107M is lower than Corcept Therapeutics's net income of $47.2M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Corcept Therapeutics's PE ratio is 40.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is -- versus 9.02x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

89bio has a net margin of -172.04% compared to Madrigal Pharmaceuticals's net margin of --. Madrigal Pharmaceuticals's return on equity of -89.04% beat 89bio's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 19.99%. On the other hand 89bio has an analysts' consensus of -- which suggests that it could grow by 277.03%. Given that 89bio has higher upside potential than Madrigal Pharmaceuticals, analysts believe 89bio is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.418, which suggesting that the stock is 141.819% less volatile than S&P 500. In comparison 89bio has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.371%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 89bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. 89bio pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $62.2M, which are larger than 89bio quarterly revenues of --. Madrigal Pharmaceuticals's net income of -$107M is higher than 89bio's net income of -$149.1M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while 89bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is -- versus -- for 89bio. Usually stocks with elevated PS ratios are considered overvalued.

Matinas BioPharma Holdings has a net margin of -172.04% compared to Madrigal Pharmaceuticals's net margin of --. Madrigal Pharmaceuticals's return on equity of -89.04% beat Matinas BioPharma Holdings's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 19.99%. On the other hand Matinas BioPharma Holdings has an analysts' consensus of -- which suggests that it could grow by 5668.12%. Given that Matinas BioPharma Holdings has higher upside potential than Madrigal Pharmaceuticals, analysts believe Matinas BioPharma Holdings is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.418, which suggesting that the stock is 141.819% less volatile than S&P 500. In comparison Matinas BioPharma Holdings has a beta of 1.672, suggesting its more volatile than the S&P 500 by 67.222%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Matinas BioPharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Matinas BioPharma Holdings pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $62.2M, which are larger than Matinas BioPharma Holdings quarterly revenues of --. Madrigal Pharmaceuticals's net income of -$107M is lower than Matinas BioPharma Holdings's net income of -$4.3M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Matinas BioPharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is -- versus 0.57x for Matinas BioPharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -172.04% compared to Madrigal Pharmaceuticals's net margin of --. Madrigal Pharmaceuticals's return on equity of -89.04% beat Viking Therapeutics's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 19.99%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 159.92%. Given that Viking Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Viking Therapeutics is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.418, which suggesting that the stock is 141.819% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.884, suggesting its less volatile than the S&P 500 by 11.566%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $62.2M, which are larger than Viking Therapeutics quarterly revenues of --. Madrigal Pharmaceuticals's net income of -$107M is lower than Viking Therapeutics's net income of -$24.9M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.